Camargo Pharmaceutical Services, a leading drug development organization specializing in the 505(b)(2) approval pathway, joined inPack to present a seminar, “Non-Clinical and Clinical Study Design Factors in a Clinical Trial Protocol,” on Dec. 9 in Tel Aviv, Israel.
“Israel has relatively high levels of generic production and pharmaceutical exporting, which is why we focused on how to conduct studies that fulfill Israeli regulations while also meeting the FDA’s requirements,” said Ken Phelps, president and CEO of Camargo.
Camargo excels at partnering with foreign drug development companies to expedite the U.S. drug approval process. The company’s expertise, sought by developers worldwide, is particularly valuable in Israel where the pharmaceutical market value will increase from approximately $1.9 billion in 2013 to $2.34 billion by 2020, according to GlobalData. Israel’s pharmaceutical exports were worth approximately $7.1 billion in 2013, more than four times the value of the country’s $1.7 billion in imports.
Attendees including clinical trial directors, regulatory affairs directors, clinical managers and clinical research associates gained invaluable information and recommendations for developing clinical trial protocols to streamline processes and reduce costs.
The collaborative seminar was jointly presented by Camargo and inPack. Learn more about inPack at www.inpack.co.il and Camargo’s services and its experience with helping developers worldwide obtain 505(b)(2) approval at www.camargopharma.com.